tumor tissues; paired adjacent normal tissues; adjacent non-tumorous tissues
BEAS-2B; A549; H1975; H460; H1299; PC-9; 293T
cell line-derived xenograft
Wnt/beta-catenin (inhibits); cell cycle (inhibits); apoptosis (promotes); ferroptosis (promotes); EMT (inhibits); proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); ceRNA regulation (other)
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; circRNA-seq; RT-qPCR; Northern Blot; FISH / smFISH; RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Transwell Assay; Wound Healing Assay; TUNEL; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); IF (Immunofluorescence); Western Blot; Clinical Sample Validation; Survival Analysis; ROC Analysis; Bioinformatics Analysis
circ_GLS has good diagnostic efficacy in NSCLC tissues; high circ_GLS expression is associated with longer overall survival and lower death risk, and circ_GLS expression correlates with N stage, TNM stage, and differentiation.
circ_GLS is a GLS-derived human circRNA that is downregulated in NSCLC tumor tissues. It suppresses malignant NSCLC phenotypes by sponging miR-410-3p and positively regulating GSK3beta, thereby inhibiting beta-catenin signaling and EMT, restraining cell-cycle progression, and promoting apoptosis and ferroptosis. Clinically, higher circ_GLS expression is associated with better overall survival and shows diagnostic potential in NSCLC tissues.
0.8868
Circ_GLS/miR-410-3p/GSK3beta/beta-catenin axis modulates malignant phenotypes of non-small cell lung cancer cells via regulation of cell cycle, apoptosis, ferroptosis, and EMT.
combined biological and clinical study